Largest pharmaceuticals by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
AbbVie leads the 35 pharmaceuticals ranked by total debt, at NOK 653.9B, ahead of Pfizer (NOK 627.8B) and Merck & Co (NOK 477.6B). Figures as of 18 Nov 2026, 14:43 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 35
- First
- AbbVieNOK 653.9B
- Median
- NOK 51.1B
- Combined market value
- NOK 49.88T
- Countries
- 10
- Not ranked
- 26no total debt on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | NOK 653.9B | NOK 5T | NOK 2,826.18 | 0.39% down | 26% up | ||
| 2 | PfizerPFE · Health Care | NOK 627.8B | NOK 1.57T | NOK 275.88 | 0.05% up | 14% up | ||
| 3 | Merck & CoMRK · Health Care | NOK 477.6B | NOK 3.37T | NOK 1,366.71 | 1.63% down | 51% up | ||
| 4 | Johnson & JohnsonJNJ · Health Care | NOK 464.4B | NOK 6.49T | NOK 2,696.55 | 0.18% down | 38% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | NOK 437.1B | NOK 1.21T | NOK 590.71 | 0.67% down | 34% up | ||
| 6 | Eli LillyLLY · Health Care | NOK 411.8B | NOK 12.22T | NOK 13,719.79 | 0.05% up | 35% up | ||
| 7 | Takeda PharmaceuticalTAK · Health Care | NOK 296.2B | NOK 668.3B | NOK 209.17 | 0.25% down | 54% up | ||
| 8 | AstraZenecaAZN · Health Care | NOK 287B | NOK 2.72T | NOK 1,754.49 | 0.62% down | 2% up | ||
| 9 | NovartisNVS · Health Care | NOK 278.3B | NOK 2.89T | NOK 1,528.20 | 0.90% down | 25% up | ||
| 10 | SanofiSNY · Health Care | NOK 201B | NOK 1.11T | NOK 461.66 | 0.25% up | 4% down | ||
| 11 | Novo NordiskNVO · Health Care | NOK 188.3B | NOK 1.72T | NOK 390.83 | 0.90% down | 17% down | ||
| 12 | GSKGSK · Health Care | NOK 185.9B | NOK 959B | NOK 478.42 | 0.31% up | 6% up | ||
| 13 | ViatrisVTRS · Health Care | NOK 139.6B | NOK 229.3B | NOK 199.97 | 0.93% up | 96% up | ||
| 14 | Abbott LaboratoriesABT · Health Care | NOK 125.3B | NOK 1.77T | NOK 1,022.14 | 0.71% up | 17% down | ||
| 15 | ZoetisZTS · Health Care | NOK 87.6B | NOK 330.9B | NOK 814.37 | 0.69% up | 29% down | ||
| 16 | Royalty PharmaRPRX · Health Care | NOK 86.7B | NOK 384.6B | NOK 668.94 | 0.53% up | 78% up | ||
| 17 | Jazz PharmaceuticalsJAZZ · Health Care | NOK 51.9B | NOK 150.4B | NOK 2,343.41 | 0.48% up | 37% up | ||
| 18 | GenmabGMAB · Health Care | NOK 51.1B | NOK 310.2B | NOK 503.03 | 0.08% down | 70% up | ||
| 19 | Elanco Animal HealthELAN · Health Care | NOK 38.9B | NOK 127.3B | NOK 254.61 | 1.66% up | 20% up | ||
| 20 | Amneal PharmaceuticalsAMRX · Health Care | NOK 24.9B | NOK 72.3B | NOK 207.43 | 1.37% up | 83% up | ||
| 21 | BridgeBio PharmaBBIO · Health Care | NOK 19.4B | NOK 145.6B | NOK 747.18 | 0.42% up | 17% up | ||
| 22 | Regeneron PharmaceuticalsREGN · Health Care | NOK 19.2B | NOK 968.6B | NOK 9,363.01 | 0.90% up | 36% up | ||
| 23 | Ionis PharmaceuticalsIONS · Health Care | NOK 17.6B | NOK 44.1B | NOK 264.50 | 1.26% up | 64% down | ||
| 24 | BeOne MedicinesONC · Health Care | NOK 10B | NOK 451.7B | NOK 3,954.36 | 1.24% down | 17% up | ||
| 25 | Ascendis PharmaASND · Health Care | NOK 7.7B | NOK 171.6B | NOK 2,615.80 | 0.44% down | 28% up | ||
| 26 | InsmedINSM · Health Care | NOK 5.3B | NOK 258.3B | NOK 1,177.25 | 0.29% down | 40% down | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | NOK 3.3B | NOK 94.5B | NOK 4,069.75 | 0.46% down | 24% down | ||
| 28 | Legend BiotechLEGN · Health Care | NOK 3.1B | NOK 31.9B | NOK 164.41 | 5.34% up | 42% down | ||
| 29 | CytokineticsCYTK · Health Care | NOK 2.8B | NOK 70.2B | NOK 503.61 | 0.64% up | 20% down | ||
| 30 | TG TherapeuticsTGTX · Health Care | NOK 2.4B | NOK 92.8B | NOK 613.81 | 1.03% up | 107% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | NOK 2.2B | NOK 48B | NOK 276.12 | 2.33% up | 20% down | ||
| 32 | Dr. Reddy's LaboratoriesRDY · Health Care | NOK 1.9B | NOK 120.8B | NOK 144.84 | 1.01% up | 5% up | ||
| 33 | Axsome TherapeuticsAXSM · Health Care | NOK 1.8B | NOK 69.2B | NOK 1,316.09 | 0.08% down | 7% down | ||
| 34 | Rhythm PharmaceuticalsRYTM · Health Care | NOK 1B | NOK 77.5B | NOK 1,118.54 | 0.99% down | 13% up | ||
| 35 | Definium TherapeuticsDFTX · Health Care | NOK 393.1M | NOK 39.1B | NOK 285.52 | 0.31% up | 169% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6885 NOK). 26 companies have no total debt on file and are not ranked here.
Questions and answers
Which pharmaceuticals rank first by total debt?
AbbVie (NOK 653.9B), Pfizer (NOK 627.8B) and Merck & Co (NOK 477.6B) are the top three of the 35 pharmaceuticals ranked by total debt as of 18 Nov 2026, 14:43 UTC.
How many pharmaceuticals are in this ranking?
35 are ranked by total debt. 26 more have no total debt on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 35 pharmaceuticals ranked by total debt have a combined market value of NOK 49.88T as of 18 Nov 2026, 14:43 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.